From: Mount Sinai School of Medicine firstname.lastname@example.org Having trouble viewing this email? Click here Abstract Submission Deadline: December 18, 2011Message 1 of 1 , Nov 28, 2011View Source
From: Mount Sinai School of Medicine iapac@...
Having trouble viewing this email? Click here
Abstract Submission Deadline: December 18, 2011
Early Registration Ends in 33 Days
March 26-27, 2012 - New York City
The Mount Sinai School of Medicine (New York), International Association of Physicians in AIDS Care (IAPAC), and St. Stephen's AIDS Trust (London), announce the 2012 International Conference on Viral Hepatitis (ICVH 2012), March 26-27, 2012, at the New York Academy of Medicine in New York City. The conference is co-chaired by Drs. Douglas T. Dieterich (Mount Sinai School of Medicine) and Mark R. Nelson (Chelsea & Westminster Hospital).
The goal of this conference is to provide an international forum for the presentation and discussion of state-of-the-science viral hepatitis research, as well as clinical perspectives in practicum, for a target audience made up of infectious disease (ID) and non-ID-specialized HIV-treating physicians, nurse-practitioners, physician-assistants, and pharmacists.Among the clinical management issues to be examined are: defining parameters for hepatitis B virus (HBV) and hepatitis C virus (HCV) treatment success; identifying and managing adherence and behavioral and clinical issues unique to patients with HBV and HCV infection; exploring the importance of preventing HBV and HCV drug resistance; and evaluating current data related to recently FDA-approved HBV and HCV treatment options (including direct action antivirals [DAAs]) and modalities. Click here to review the conference program.Conference Faculty
The following speakers have been invited to serve on the ICVH 2012 faculty:
Scott M. Hammer, MD, Columbia University * New York, NY, USA
Are HIV and Other Chronic Disease Models Applicable to Viral Hepatitis?
David Back, MD, University of Liverpool * Liverpool, UK
PK and Drug Interactions in the New HCV Clinical Management SOC
Douglas T. Dieterich, MD, Mount Sinai School of Medicine * New York, NY, USA
New Directions in Viral Hepatitis - New Interferons and Immunomodulatory Therapy
Agarwal Koch, MD, King's College * London, UK
What Do Data in Viral Hepatitis Monoinfection Mean in Relation to Coinfection?
Michael Mugavero, MD, University of Alabama, Birmingham * Birmingham, AL, USA
Adherence in the Age of HCV Antivirals: Lessons from HIV Adherence Intervenions
Calvin Q. Pan, MD, Mount Sinai School of Medicine * New York, NY, USA
HBV Management in 2012... Where Are We Heading?
Jonathan M. Schapiro, MD, Sheba Medical Center * Tel Aviv, ISRAEL
Resistance to HCV Direct-Acting Antivirals
Thomas D. Schiano, MD, Mount Sinai School of Medicine * New York, NY, USA
Liver Transplant in HIV-Positive Patients
Kenneth E. Sherman, MD, University of Cincinnati * Cincinnati, OH, USA
Overview: Hepatitis D and E Clinical Management
Vincent Soriano, MD, PhD, Hospital Carlos III * Madrid, SPAIN
Non-Cirrhotic Portal Hypertension
Mark S. Sulkowski, MD, John Hopkins School of Medicine * Baltimore, MD, USA
The Direct-Acting Antivirals in our Quiver... and Those we Might Have Soon
Marie-Louise C. Vachon, MD, University of Québec * Québec City, CANADA
The Aging Liver in HIV
Ronald Valdisseri, MD, US DHHS * Washington, DC, USA
Health Workforce Bottleneck - Expanding the University of Viral Hepatitis TreatersAccreditation Statements
The Mount Sinai School of Medicine is accredited by the Accrediation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians. The conference is accredited by the Mount Sinai School of Medicine for a maximum of 12.5 AMA PRA Category 1 Credits.TM
The Association of Nurses in AIDS Care (ANAC) is an approved provider of continuing nursing education by the Virginia Nurses Association's Continuing Education Committee, an accredited approver by the American Credentialing Center's Commission of Accreditation. The conference is approved by ANAC for 12.5 contact hours.
Call for Abstracts
The ICVH 2012 organizers invite the submission of abstracts in the following areas:HCV clinical management
- Acute viral hepatitis
- HIV and hepatitis drug pharmacology
- Genetic markers and treatment response
- Drug resistance
- Treatment adherence
- New treatment options and modalities
- Special hepatic issues
The deadline for submitting abstracts is December 18, 2011. All abstracts must be submitted electronically. Click here to review the abstract submission guidelines and/or to submit an abstract(s).
Registration, Hotel Accommodations
Online registration is now open. The Early Registration rate is $175 for IAPAC members and $275 for non-IAPAC members. The Early Registration deadline is January 1, 2012. Click here to register for ICVH 2012 today!
A discounted room block is available for conference participants at The Empire Hotel, with complimentary shuttle service to the conference venue (New York Academy of Medicine). Delegates who elect to book their accommodations at The Empire Hotel will also receive a $50 discount on their conference registration. Click here for more information about The Empire Hotel and/or about booking your reservations.This email was sent to events_updates@... by iapac@... |IAPAC | 123 W Madison Street | Suite 1400 | Chicago | IL | 60602
Press OK to abandon changes or Cancel to continue editing
- Changes have not been saved
Kindly note that Groups does not support 7.0 or earlier versions of Internet Explorer. We recommend upgrading to the latest Internet Explorer, Google Chrome, or Firefox. If you are using IE 9 or later, make sure you turn off Compatibility View.
- Your browser is not supported